<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140078" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pseudoexfoliation Syndrome and Glaucoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tuteja</surname>
            <given-names>Sahib</given-names>
          </name>
          <aff>Newcastle Upon Tyne Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zeppieri</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>University Hospital of Udine, Italy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chawla</surname>
            <given-names>Harshika</given-names>
          </name>
          <aff>Sunderland Eye Infirmary</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sahib Tuteja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Zeppieri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harshika Chawla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140078.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pseudoexfoliation syndrome is a chronic, age-related disorder of the extracellular matrix that results in the deposition of abnormal fibrillary (pseudoexfoliative) material within various body tissues. This condition manifests primarily in the anterior segment of the eye. Individuals with this condition can develop pseudoexfoliation glaucoma in the presence of chronic elevated intraocular pressure, glaucomatous optic neuropathy, and visual field damage. This activity reviews the evaluation and treatment of pseudoexfoliation syndrome and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the risk factors for developing pseudoexfoliation syndrome (PEX) and pseudoexfoliation glaucoma (PEG).</p></list-item><list-item><p>Describe the clinical features of PEX and PEG.</p></list-item><list-item><p>Explain the risks associated with cataract surgery in PEX and PEG.</p></list-item><list-item><p>Summarize the management and follow-up of patients diagnosed with PEX and PEG.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140078&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140078">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140078.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pseudoexfoliation syndrome (PEX) is a systemic disorder that leads to the accumulation of extracellular material in various ocular tissues, <xref ref-type="bibr" rid="article-140078.r1">[1]</xref> which presents primarily via its characteristic ocular manifestations.<xref ref-type="bibr" rid="article-140078.r2">[2]</xref> PEX is considered an age-related microfibillopathy that affects different systemic organs and is characterized by a progressive chronic deposition and accumulation of extracellular greyish-white material in several organs.<xref ref-type="bibr" rid="article-140078.r3">[3]</xref> PEX can lead to secondary glaucoma, known as pseudoexfoliative glaucoma (PEG), which is a major cause of blindness worldwide.</p>
        <p>This systemic disorder is typically clinically diagnosed during routine ophthalmic examination with slit-lamp visualization of white, flaky fibrillar (pseudoexfoliative) material on the pupillary margin of the iris and the anterior lens capsule.<xref ref-type="bibr" rid="article-140078.r4">[4]</xref> This condition affects the eyes, particularly the lens and the trabecular meshwork, which are responsible for regulating the flow of fluid in the eye.<xref ref-type="bibr" rid="article-140078.r5">[5]</xref> Small flakes of material, resembling dandruff, tend to accumulate on the surface of the lens, the iris, and the ciliary body. This accumulation can cause increased intraocular pressure (IOP) inside the eye, leading to glaucoma and other vision problems. PEX is more common in individuals over the age of 60 and is often associated with a higher risk of cataract development. While there is currently no cure for PEX, early diagnosis, and treatment can help prevent or slow the progression of vision loss.</p>
        <p>The history of PEX dates back to the early 20th century in 1917 when John G. Lindberg first described the characteristic flaky material found in the eyes of patients with glaucoma.<xref ref-type="bibr" rid="article-140078.r6">[6]</xref> However, it wasn't until the 1950s that the term "Pseudoexfoliation" was used to describe the condition.<xref ref-type="bibr" rid="article-140078.r7">[7]</xref> Initially, PEX was thought to be a benign age-related change in the eye, but as more research was conducted, it became clear that PEX was associated with an increased risk of glaucoma and other vision problems. Since then, PEX has been extensively studied, and numerous researchers have contributed to our understanding of the condition's pathogenesis, genetics, and clinical implications. Despite ongoing research, the exact cause of PEX remains unclear, and there is currently no cure for the condition.</p>
        <p>PEX may be present unilaterally or bilaterally. PEX is strongly associated with raised intraocular pressures (IOP) in up to 44% of patients and subsequent development of pseudoexfoliation glaucoma (PEG), making it the most commonly identifiable cause of secondary open-angle glaucoma.<xref ref-type="bibr" rid="article-140078.r8">[8]</xref>&#x000a0;PEX is also associated with technically challenging cataract surgery: PEX eyes dilate poorly and have unstable lens zonules, which may lead to a higher risk of complications such as capsular bag rupture, zonular dialysis, and loss of vitreous.<xref ref-type="bibr" rid="article-140078.r9">[9]</xref></p>
      </sec>
      <sec id="article-140078.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>PEX is characterized by the formation of white, flaky deposits on the lens and iris, which can cause several ocular complications, including cataracts, glaucoma, and corneal endothelial dysfunction. The exact etiology of PEX is not known, however, genetic susceptibility is supported by numerous genetic studies in population studies worldwide.<xref ref-type="bibr" rid="article-140078.r10">[10]</xref> Variants of certain genes have been found to be more common in individuals with PEX and PEG, suggesting that they may play a role in the development of the condition.</p>
        <p>A genetic predisposition has been shown for the following genes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lysyl oxidase-like 1 (LOXL1) enzyme is part of a family of copper-dependent monoamine oxidases secreted by fibroblasts and smooth muscle cells. These enzymes are involved in cross-linking collagen and elastin fibers in the extracellular matrix. Multiple single nucleotide polymorphisms (SNPs) in this gene are associated with PEX, and various high-risk alleles have been identified in different populations, with important associations between LOLX1 and PEX in individuals from Scandinavia, Europe, Asia, Africa, Australia, and North America.<xref ref-type="bibr" rid="article-140078.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Chromosome 8p21, Clusterin (CLU) gene: Clusterin is a multifunctional glycoprotein that has been proposed to inhibit stress-induced aggregation of misfolded proteins. Clusterin downregulation has been shown to occur in all anterior segment tissues in PEX eyes, suggesting that its deficiency may be responsible for the chronic accumulation of abnormal extracellular fibrillar material in this condition.<xref ref-type="bibr" rid="article-140078.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Calcium Voltage-Gated Channel Subunit Alpha 1 (CACNA1A): Gene variants could possibly influence calcium levels that may lead to PEX depositions.<xref ref-type="bibr" rid="article-140078.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Chromosome 1p13.3, Glutathione transferase (GST) gene: GST has a role in protecting cells from oxidative damage. Polymorphisms of GST have been detected in Pakistani patients with PEX. However, no significant association was found in other patient populations.<xref ref-type="bibr" rid="article-140078.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Fibulin-5 (FBLN5) gene: Studies have shown that downregulation of two variants of this gene that encode for this extracellular matrix protein have been associated with risks of developing PEG.<xref ref-type="bibr" rid="article-140078.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>PEX deposits are composed of different extracellular, molecular, and membrane proteins and enzymes that include tropoelastin, fibrillin-1, elastin, LOL1, amyloid, fibulin, vitronectin, clusterin, etc.<xref ref-type="bibr" rid="article-140078.r5">[5]</xref> Genetic variants or mutations that cause dysregulation and production of these components can potentially be of importance in the genetic susceptibility for PEX and PEG.<xref ref-type="bibr" rid="article-140078.r16">[16]</xref> Other genetic associations have also been discovered, including polymorphisms of the CNTNAP2 gene,<xref ref-type="bibr" rid="article-140078.r17">[17]</xref> vimentin, <xref ref-type="bibr" rid="article-140078.r18">[18]</xref> tumor necrosis factor-alpha, tumor growth factor beta 1, matrix metalloproteinase-1, and 3, proteasome maturation protein (POMP), transmembrane protein 136, semaphorin 6A (SEMA6A), etc.<xref ref-type="bibr" rid="article-140078.r10">[10]</xref><xref ref-type="bibr" rid="article-140078.r19">[19]</xref> Current studies have reported the presence of altered microRNA molecules, which regulate post-transcriptional gene expression, in the aqueous humor of individuals with PEX and PEG.<xref ref-type="bibr" rid="article-140078.r20">[20]</xref></p>
        <p>Environmental factors that have been proposed to play a role in the development of PEX include exposure to sunlight and ultraviolet light,<xref ref-type="bibr" rid="article-140078.r21">[21]</xref> long-term alcohol consumption,<xref ref-type="bibr" rid="article-140078.r22">[22]</xref> excessive caffeine,<xref ref-type="bibr" rid="article-140078.r23">[23]</xref> higher temperatures, climatic and geographical factors, diet, viral infection, and trauma or surgery involving the anterior segment.<xref ref-type="bibr" rid="article-140078.r11">[11]</xref><xref ref-type="bibr" rid="article-140078.r24">[24]</xref> Current studies have shown that factors associated with increased oxidative stress, production of free radicals, disruption of the blood-aqueous barrier, and limited antioxidant defense mechanisms can play important roles in the etiopathogenesis of PEX and PEG.<xref ref-type="bibr" rid="article-140078.r25">[25]</xref><xref ref-type="bibr" rid="article-140078.r10">[10]</xref></p>
        <p>The insoluble extracellular aggregates in the anterior chamber can decrease aqueous humor outflow and congestion in the trabecular meshwork, causing large fluctuations and increases in IOP, thus leading to PEG in some individuals with PEX. PEG is a type of secondary glaucoma as a result of PEX, which is a progressive disease that can lead to blindness if left untreated. Signs of this type of secondary glaucoma include irreversible optic nerve head and retinal nerve fiber layer damage and/or visual field defects,<xref ref-type="bibr" rid="article-140078.r26">[26]</xref> which tend to be more severe and progress at faster rates when compared to primary open-angle glaucoma (POAG).<xref ref-type="bibr" rid="article-140078.r27">[27]</xref><xref ref-type="bibr" rid="article-140078.r26">[26]</xref></p>
      </sec>
      <sec id="article-140078.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of PEX increases markedly with age. It is estimated that up to 20% of the over-60 population may be affected.<xref ref-type="bibr" rid="article-140078.r4">[4]</xref> PEX is found in all geographic populations with a significant variation in prevalence, which range from 0% to 38%.<xref ref-type="bibr" rid="article-140078.r28">[28]</xref> In populations of Scandinavian, Northern European, and Mediterranean descent, the prevalence of PEX is estimated to be between 5% and 20%. Nordic and Eastern Mediterranean countries are most affected, and East Asian and Inuit populations have the lowest reported prevalence. Studies have reported that the prevalence of PEX can be as low as 0% in Greenland Inuits<xref ref-type="bibr" rid="article-140078.r29">[29]</xref> and as high as 38 % in Navajo Nation Indians.<xref ref-type="bibr" rid="article-140078.r30">[30]</xref>The variation in prevalence has been proposed to be due to epigenetics, the attitude of inhabitants, UV exposure, climatic conditions, proximity to the equator, dietary factors, oxidative stress mechanisms, genetic predisposition, etc.<xref ref-type="bibr" rid="article-140078.r31">[31]</xref><xref ref-type="bibr" rid="article-140078.r32">[32]</xref>&#x000a0;</p>
        <p>Risk Factors include:<bold/></p>
        <list list-type="bullet">
          <list-item>
            <p>Age (strongest risk factor; PEX rarely occurs below the age of 50, with an incidence increasing with age).<xref ref-type="bibr" rid="article-140078.r26">[26]</xref><xref ref-type="bibr" rid="article-140078.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Race (Nordic and Eastern Mediterranean populations have increased risk).<xref ref-type="bibr" rid="article-140078.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>high altitude and/or solar/cosmic radiation.<xref ref-type="bibr" rid="article-140078.r35">[35]</xref><xref ref-type="bibr" rid="article-140078.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Female sex (possible risk factor with more recent studies showing equal prevalence in males and females). Studies reporting on association with gender have produced conflicting results, and so the link remains unclear.<xref ref-type="bibr" rid="article-140078.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Low consumption of dietary anti-oxidants, smoking, caffeine, alcohol, and factors that favor oxidative stress<xref ref-type="bibr" rid="article-140078.r10">[10]</xref><xref ref-type="bibr" rid="article-140078.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>The diagnosis of secondary glaucoma or PEG is reached when PEX is associated with elevated and fluctuating IOP levels, in addition to functional alterations in computerized perimetry and/or defects in the optic nerve and retinal nerve fiber layer. PEG accounts for 25 % of individuals with open-angle glaucoma worldwide, in which PEX shows a cumulative probability to develop in PEG in 15% of cases within 10 years.<xref ref-type="bibr" rid="article-140078.r38">[38]</xref> There is progressive damage and loss of retinal ganglion cells that cause irreversible peripheral vision loss in PEG.</p>
      </sec>
      <sec id="article-140078.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PEX material is most readily found in the structures of the eye bathed by the aqueous. PEX is a systemic disorder that causes the accumulation of extracellular material in various other organs and body tissues including blood vessels, lungs, heart, liver, gallbladder, kidneys, meninges, and skin.<xref ref-type="bibr" rid="article-140078.r1">[1]</xref><xref ref-type="bibr" rid="article-140078.r39">[39]</xref></p>
        <p>The exact pathophysiological processes that underline PEX remain unclear. Still, it is now well known that PEX is a fibrillopathy. PEX material arises from the abnormal accumulation of elastic microfibrils composed of fibrillin-1, fibulin-2, vitronectin, the enzyme lysyl oxidase, and clusterin, amongst other proteins.<xref ref-type="bibr" rid="article-140078.r16">[16]</xref> Fibrillin molecules aggregate to form microfibrils which are then crosslinked to form PEX fibrils. &#x000a0;</p>
        <p>Transforming growth factor-beta 1 (TGF-B1) is considered a key mediator of abnormal accumulation of PEX material. It has been shown to promote PEX material formation in vitro and, increased concentrations have been found in the aqueous humor of PEX eyes. There is evidence that oxidative stress plays a role in developing PEX.<xref ref-type="bibr" rid="article-140078.r40">[40]</xref> Decreased levels of ascorbic acid and increased levels of oxidative stress markers have been found in aqueous humor. Iris hypoperfusion and anterior chamber hypoxia are also associated with PEX.</p>
        <p>The vasoconstrictor endothelin-1 is found in increased concentrations in PEX, and nitric oxide (a vasodilator) is reduced. It has been suggested that this may further exacerbate cellular stress and lead to the processes behind the development of PEX. Accumulation of abnormal PEX fibrils may be promoted via a deficiency of clusterin, a molecular chaperone that inhibits aggregation of misfolded proteins. Moreover, the dysfunction of matrix metalloproteinases (MMPs) prevents the breakdown and clearance of this abnormal material.<xref ref-type="bibr" rid="article-140078.r4">[4]</xref></p>
      </sec>
      <sec id="article-140078.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Light microscopy of anterior segment structures demonstrates deposition of PEX material on the iris pigment epithelium, anterior lens capsule, and corneal endothelium (See image of PEX).<xref ref-type="bibr" rid="article-140078.r41">[41]</xref><xref ref-type="bibr" rid="article-140078.r42">[42]</xref> Electron microscopy and immunohistochemical studies have demonstrated the production of PEX material by the non-pigmented epithelial cells of the ciliary body, iris pigment epithelium, pre-equatorial lens epithelium, and corneal endothelium.<xref ref-type="bibr" rid="article-140078.r43">[43]</xref> PEX material seen on the anterior lens capsule and the zonular fibers is thought to be transmitted from the cellular tissues via the aqueous.<xref ref-type="bibr" rid="article-140078.r44">[44]</xref></p>
        <p>Zonular weakness is a characteristic feature of PEX, and loosening of the zonular attachments to the basement membrane of the ciliary body is considered to be primarily responsible for this. This is aggravated by further weakness along the free zonular fibers and their attachment to the basement membrane of the lens capsule. Electron microscopies of conjunctival biopsies taken from fellow eyes in unilateral cases demonstrate the presence of subclinical pseudoexfoliative material, confirming that PEX is a bilateral condition with marked clinical asymmetry.<xref ref-type="bibr" rid="article-140078.r45">[45]</xref><xref ref-type="bibr" rid="article-140078.r46">[46]</xref></p>
      </sec>
      <sec id="article-140078.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PEX and PEG are typically diagnosed during a comprehensive eye exam. The presence of flaky deposits on the lens and iris is a hallmark of PEX, while an increase in IOP is a characteristic of PEG. Other tests that may be performed include visual field testing, optic nerve imaging, and gonioscopy. Patients are often asymptomatic but may present with peripheral visual field loss from secondary glaucoma or PEG. The diagnosis is made clinically via characteristic slit-lamp biomicroscopy and gonioscopic findings:</p>
        <p>
<bold>Slit Lamp Examination</bold>
</p>
        <p>The characteristic finding in PEX is the visualization of white, flaky, dandruff-like PEX material along the pupillary margin and anterior lens capsule (See image of PEX deposits on anterior structures). The anterior lens capsule shows a central disc and peripheral ring of PEX material with a clear intermediate zone maintained by pupillary abrasion. The whitish double concentric ring that is seen on the anterior portion of the lens is probably due to the movement of the iris over the lens. The central disc may be absent in up to 20% of cases, and the peripheral zone may not be completely visualized without the aid of pharmacological dilation.<xref ref-type="bibr" rid="article-140078.r47">[47]</xref></p>
        <p>A thorough, systematic examination may reveal additional signs. The corneal endothelium may show deposition of PEX material that may be erroneously interpreted as keratic precipitates or inflammatory debris. Fine scattered pigment deposits are also present, which may form a vertical line known as a Krukenberg spindle, similar to what may be seen in pigment dispersion syndrome.<xref ref-type="bibr" rid="article-140078.r48">[48]</xref> Studies have shown lower corneal endothelial cell counts and guttae in eyes with PEX.<xref ref-type="bibr" rid="article-140078.r49">[49]</xref></p>
        <p>The aqueous humor may demonstrate PEX particles and mild flare from an impaired blood-aqueous barrier. The iris may demonstrate poor mydriasis secondary to atrophy of the dilator muscle and loss of elasticity due to PEX material accumulation within the iris stroma.<xref ref-type="bibr" rid="article-140078.r41">[41]</xref> There may be a loss of pupillary ruff due to rubbing against the lens, and transillumination defects may be seen along the pupillary margin.<xref ref-type="bibr" rid="article-140078.r50">[50]</xref> This is in contrast to the more mid-peripheral iris transillumination seen in pigment dispersion syndrome.</p>
        <p>There may be phacodonesis or lens subluxation/dislocation secondary to zonular weakness. The fragility is thought to be due to the deposition of extracellular material on the zonules and ciliary processes and/or histological fiber alteration.<xref ref-type="bibr" rid="article-140078.r44">[44]</xref> Studies have reported an increased incidence of nuclear sclerotic and subcapsular cataracts in PEX eyes compared to non-PEX eyes, although the pathophysiology is not yet understood.<xref ref-type="bibr" rid="article-140078.r51">[51]</xref><xref ref-type="bibr" rid="article-140078.r52">[52]</xref></p>
        <p>
<bold>Gonioscopy</bold>
</p>
        <p>Gonioscopy is fundamental and should be performed in all patients with PEX during slit-lamp examination. PEX deposits may be visualized over angle structures. Patchy hyperpigmentation over the trabecular meshwork and Schwalbe line can be observed.<xref ref-type="bibr" rid="article-140078.r53">[53]</xref> This hyperpigmentation may coalesce to form a band of hyperpigmentation on the Schwalbe line known as the Sampaolesi line.<xref ref-type="bibr" rid="article-140078.r54">[54]</xref> In unilateral cases where no PEX material is visible in the fellow eye, trabecular meshwork pigmentation may be an early sign of PEX development. Up to 20% of PEX eyes may have occludable angles predisposing them to acute angle-closure glaucoma.<xref ref-type="bibr" rid="article-140078.r4">[4]</xref><xref ref-type="bibr" rid="article-140078.r9">[9]</xref><bold>
</bold></p>
      </sec>
      <sec id="article-140078.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>All patients suspected of PEX should undergo a dilated slit-lamp examination and gonioscopy. Baseline IOP must be measured at the time of diagnosis and periodically due to the high risk of developing ocular hypertension and PEG.<xref ref-type="bibr" rid="article-140078.r55">[55]</xref> Genetic testing of eyes is not routinely performed, considering that PEX is a clinical diagnosis.</p>
        <p>The evaluation of patients suspected of PEG is identical to those suspected of primary open-angle glaucoma (POAG).<xref ref-type="bibr" rid="article-140078.r56">[56]</xref></p>
        <p>To summarise, the clinical evaluation involves:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Visual examination of optic nerve head:</italic> This is evaluated using a slit lamp and condensing lens of sufficient magnification. The typical signs associated with glaucomatous damage include an increased cup-to-disc ratio (CDR) greater than 0.5, optic nerve cupping and notching (See image of glaucomatous optic nerve cupping), asymmetry of CDR between both eyes and disc hemorrhages.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">IOP measurement:</italic> Glaucomatous damage in pseudoexfoliation is associated with raised IOP and shows marked variation in diurnal IOP levels. IOP should therefore be measured at multiple different times of the day. Goldmann applanation tonometry is the gold standard for assessment,<xref ref-type="bibr" rid="article-140078.r57">[57]</xref> although clinicians should consider the effect of central corneal thickness on the measured value.<xref ref-type="bibr" rid="article-140078.r58">[58]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Visual Field Analysis:</italic> Static computer automated perimetry is useful for a baseline investigation of glaucoma suspects and monitoring progression in those with confirmed glaucoma. Characteristic field defects are seen as with POAG, but those seen with PEG are typically more severe and tend to progress at a faster rate.<xref ref-type="bibr" rid="article-140078.r59">[59]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Optical coherence tomography (OCT)</italic>: Peripapillary retinal nerve fiber layer (RNFL) thinning is associated with glaucomatous damage. Inferotemporal thinning tends to be associated with early glaucomatous changes, whereas superotemporal thinning may be used to differentiate severe glaucoma from healthy controls.<xref ref-type="bibr" rid="article-140078.r60">[60]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140078.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is currently no treatment available to halt the deposition of PEX material in affected eyes. Management of this condition is primarily aimed at regular (at least annual) eye examinations for early detection and treatment of glaucoma.</p>
        <p><italic toggle="yes">Local eye drops:</italic> The first-line treatment of PEG is medical. IOP-lowering topical medications that are effective in PEG include prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, or a combination of these. Pilocarpine is not recommended due to the risk of worsening angle-closure glaucoma and posterior synechiae formation. PEG is generally more resistant to medical therapy than POAG. Considering the aggressive nature and the risk of faster progression in PEX, the target IOP should be lower than those used to manage POAG.<xref ref-type="bibr" rid="article-140078.r59">[59]</xref></p>
        <p><italic toggle="yes">Selective laser trabeculoplasty (SLT): </italic>Laser treatment may be used as a first-line treatment or to avoid more invasive surgery. It is very successful in PEG eyes, reducing IOP by 30%. The increased effectiveness of SLT may be due to the increased pigmentation of the trabecular meshwork, which leads to increased absorption of laser energy. SLT, however, is not permanent, and a significant proportion of patients may require further surgery in the long term. Argon laser trabeculoplasty (ALT), which induces a greater histopathological effect on the trabecular meshwork due to the stronger energy laser applied for a longer time, has also been reported to be useful as a temporary regulation treatment of IOP in PEG.<xref ref-type="bibr" rid="article-140078.r61">[61]</xref> SLT has shown to be less destructive and can be repeatable, thus a viable alternative to traditional ALT.<xref ref-type="bibr" rid="article-140078.r62">[62]</xref></p>
        <p><italic toggle="yes">Surgery:</italic> Similar to POAG, surgical management of PEG may be considered following the failure of maximal medical therapy and/or SLT.<xref ref-type="bibr" rid="article-140078.r63">[63]</xref> Trabeculectomy in PEG patients has shown similar outcomes as with POAG patients, without an increased risk of complications.<xref ref-type="bibr" rid="article-140078.r64">[64]</xref> Glaucoma drainage devices and alternative methods like canaloplasty and viscocanalostomy may also be considered, although target pressures after surgery do not tend to be low, thus local eyedrops may still be needed in some patients.<xref ref-type="bibr" rid="article-140078.r65">[65]</xref> If there is a component of angle closure secondary to cataract or anterior lens movement secondary to zonular laxity, laser iridoplasty or cataract extraction may be beneficial.<xref ref-type="bibr" rid="article-140078.r66">[66]</xref></p>
        <p>Cataract surgery may be challenging in PEX eyes due to poor mydriasis, corneal endotheliopathy, zonular instability, and lens subluxation.<xref ref-type="bibr" rid="article-140078.r67">[67]</xref> Zonular laxity may predispose to zonular dialysis, compromised blood-aqueous barrier, capsular bag rupture, and subsequent loss of vitreous.<xref ref-type="bibr" rid="article-140078.r68">[68]</xref> There is also an increased risk of postoperative complications, which include increased inflammation, iris vascular leaks, spikes in IOP, corneal edema, capsular opacification, capsular phimosis, and late intra-ocular lens (IOL) decentration.<xref ref-type="bibr" rid="article-140078.r69">[69]</xref> PEX patients often need a more aggressive and longer duration of treatment with postoperative steroids. Therefore, it is essential to evaluate all eyes undergoing cataract extraction for the presence of pseudoexfoliation to aid surgical planning, prognostication, and follow-up.<xref ref-type="bibr" rid="article-140078.r67">[67]</xref></p>
        <p>Current studies in the literature have shown that new treatments for PEG are constantly being studied. These alternatives to traditional treatment are still being performed in preclinical and animal models, and include magnetic phage display,<xref ref-type="bibr" rid="article-140078.r70">[70]</xref> microRNAs,<xref ref-type="bibr" rid="article-140078.r71">[71]</xref>gene therapies,<xref ref-type="bibr" rid="article-140078.r72">[72]</xref> stem cell therapy,<xref ref-type="bibr" rid="article-140078.r73">[73]</xref> nanotechnology,<xref ref-type="bibr" rid="article-140078.r74">[74]</xref> immunotherapy,<xref ref-type="bibr" rid="article-140078.r75">[75]</xref> and photobiomodulation.<xref ref-type="bibr" rid="article-140078.r76">[76]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-140078.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Pigment dispersion syndrome:</italic> Corneal endothelial changes are similar to those of PEX (Krukenberg spindle).<xref ref-type="bibr" rid="article-140078.r77">[77]</xref> Iris transillumination demonstrates mid-peripheral atrophy as compared to the pupillary border defects seen in PEX. Gonioscopy shows posterior bowing of the iris and more homogenous trabecular meshwork pigmentation than the patchy pigmentation seen in PEX.<xref ref-type="bibr" rid="article-140078.r78">[78]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">True exfoliation of the lens capsule: </italic>This is a rare disorder where the superficial and deeper layers of the anterior lens capsule separate in association with exposure to infrared radiation. Slit-lamp examination shows a thin white membrane emanating from the lens into the anterior chamber.<xref ref-type="bibr" rid="article-140078.r79">[79]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Amyloidosis:</italic> Amyloid can appear similar to PEX material and deposit within the anterior segment structures.<xref ref-type="bibr" rid="article-140078.r80">[80]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Primary open-angle glaucoma: </italic>There are no signs of white, flaky deposits on the anterior segment of the eye.<xref ref-type="bibr" rid="article-140078.r81">[81]</xref><italic toggle="yes"/></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Primary angle-closure glaucoma: </italic>Elevated IOP is due to angle closure without the presence of PEX material.<xref ref-type="bibr" rid="article-140078.r82">[82]</xref><italic toggle="yes"/></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140078.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PEX is significantly associated with the development of glaucoma. In one study, 44% of patients diagnosed with PEX developed ocular hypertension requiring treatment or glaucoma within 15 years of follow-up. In patients diagnosed with unilateral PEX, the risk of the fellow eye developing clinically evident PEX was 29% by 15 years.<xref ref-type="bibr" rid="article-140078.r8">[8]</xref> When compared to POAG, PEX eyes have higher IOPs with an increased diurnal variation. There is a rapid progression of nerve damage, and subsequent field loss may be worse than POAG.</p>
      </sec>
      <sec id="article-140078.s12" sec-type="Complications">
        <title>Complications</title>
        <p>PEX eyes may be complicated by progression to ocular hypertension or glaucoma (PEG). Cataract surgery may be challenging in these eyes because of corneal endotheliopathy, poor mydriasis, lens subluxation, and zonular instability.<xref ref-type="bibr" rid="article-140078.r67">[67]</xref> Cataract surgical complications include corneal edema, compromised blood-aqueous barrier, capsular opacification, spikes in IOP, capsular phimosis, increased inflammation, zonular dialysis, capsular bag rupture, iris vascular leaks, and late intra-ocular lens (IOL) decentration.<xref ref-type="bibr" rid="article-140078.r68">[68]</xref> PEX and PEG patients tend to require more frequent follow-ups and aggressive therapies in the presence of elevated IOP and signs of glaucomatous functional and anatomical progression.</p>
      </sec>
      <sec id="article-140078.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be advised to seek annual eye screening to develop ocular hypertension and/or glaucoma. Patients on medical therapy must be advised on the importance of treatment adherence in preventing the progression of glaucomatous damage. Those undergoing cataract surgery must be counseled regarding the increased risks associated with surgery and the possible need for further surgery if there are associated complications. They should be advised of the risk of IOL decentration years following the surgery. PEX is significantly associated with cardiovascular and cerebrovascular disease, and patients may be advised to seek optimization of vascular risk factors with their primary care physician.<xref ref-type="bibr" rid="article-140078.r83">[83]</xref></p>
      </sec>
      <sec id="article-140078.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Untreated glaucoma may lead to severe peripheral vision loss, followed by central visual loss. Patient outcomes can be improved through ophthalmologist collaboration with other healthcare professionals within the community setting. Community optometrists are well-equipped to perform routine eye examinations, monitor patients&#x02019; intraocular pressures, and perform perimetry testing. They are aiming to refer all glaucoma suspects to secondary care. Patients diagnosed with glaucoma need to be closely monitored and provided with ongoing education. The primary care physician can work with patients to treat co-morbidities that may impair the self-administration of eye drops such as arthritis of the hands and optimize vascular risk factors that may be elevated in this patient group. [Level 5]</p>
      </sec>
      <sec id="article-140078.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140078&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140078">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/pseudoexfoliation-syndrome-and-glaucoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140078">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140078/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140078">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140078.s16">
        <fig id="article-140078.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Slit lamp photograph of a left eye demonstrating pseudoexfoliation material on the pupillary margin Contributed by Sahib Tuteja, MBChB</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Pupillary__PEX" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140078.s17">
        <fig id="article-140078.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Individual with pseudoexfoliation syndrome (PEX) and cataract. PEX is clinically diagnosed with slit-lamp visualization of white, flaky fibrillar (pseudoexfoliative) material on the pupillary margin of the iris and the anterior lens capsule. Contributed by Mutali Musa, OD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PEX" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140078.s18">
        <fig id="article-140078.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Glaucomatous optic nerve cupping in a patient with pseudoexfoliation glaucoma (PEG). Contributed by Marco Zeppieri, MD, PhD. Image courtesy of Paolo Brusini, MD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Papilla__SPEX" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140078.s19">
        <title>References</title>
        <ref id="article-140078.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mastronikolis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pagkalou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baroutas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kyriakopoulou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makri</surname>
                <given-names>&#x0039f;E</given-names>
              </name>
              <name>
                <surname>Georgakopoulos</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Pseudoexfoliation syndrome: The critical role of the extracellular matrix in pathogenesis and treatment.</article-title>
            <source>IUBMB Life</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>995</fpage>
            <page-range>995-1002</page-range>
            <pub-id pub-id-type="pmid">35201654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padhy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alone</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Is pseudoexfoliation glaucoma a neurodegenerative disorder?</article-title>
            <source>J Biosci</source>
            <year>2021</year>
            <volume>46</volume>
            <pub-id pub-id-type="pmid">34785624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pompoco</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paulson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shumway</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Conley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Swiston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stagg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wirostko</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Summary of Utah Project on Exfoliation Syndrome (UPEXS): using a large database to identify systemic comorbidities.</article-title>
            <source>BMJ Open Ophthalmol</source>
            <year>2021</year>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>e000803</fpage>
            <pub-id pub-id-type="pmid">34765740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
            </person-group>
            <article-title>Ocular and systemic pseudoexfoliation syndrome.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2006</year>
            <month>May</month>
            <volume>141</volume>
            <issue>5</issue>
            <fpage>921</fpage>
            <page-range>921-937</page-range>
            <pub-id pub-id-type="pmid">16678509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Challa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Composition of Exfoliation Material.</article-title>
            <source>J Glaucoma</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>27 Suppl 1</volume>
            <fpage>S29</fpage>
            <page-range>S29-S31</page-range>
            <pub-id pub-id-type="pmid">29965899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grzybowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kanclerz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The History of Exfoliation Syndrome.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-61</page-range>
            <pub-id pub-id-type="pmid">30421589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bansal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spivey</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Honavar</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>PXF, the power of the X-factor - Georgiana Dvorak-Theobald.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>359</fpage>
            <page-range>359-360</page-range>
            <pub-id pub-id-type="pmid">35086196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeng</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Karger</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Good</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The risk of glaucoma in pseudoexfoliation syndrome.</article-title>
            <source>J Glaucoma</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-21</page-range>
            <pub-id pub-id-type="pmid">17224761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plateroti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Plateroti</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Abdolrahimzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scuderi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma: A Review of the Literature with Updates on Surgical Management.</article-title>
            <source>J Ophthalmol</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>370371</fpage>
            <pub-id pub-id-type="pmid">26605078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mastronikolis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pagkalou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plotas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kagkelaris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Georgakopoulos</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Emerging roles of oxidative stress in the pathogenesis of pseudoexfoliation syndrome (Review).</article-title>
            <source>Exp Ther Med</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>602</fpage>
            <pub-id pub-id-type="pmid">35949329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhawy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kamthan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>CQ</given-names>
              </name>
              <name>
                <surname>Danias</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pseudoexfoliation syndrome, a systemic disorder with ocular manifestations.</article-title>
            <source>Hum Genomics</source>
            <year>2012</year>
            <month>Oct</month>
            <day>10</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">23157966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zenkel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kruse</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>J&#x000fc;nemann</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2006</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>1982</fpage>
            <page-range>1982-90</page-range>
            <pub-id pub-id-type="pmid">16639006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizoguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Allingham</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haripriya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uebe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harder</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Burdon</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Astakhov</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Abu-Amero</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Zenteno</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nilg&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zarnowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pakravan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Safieh</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paoli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schlottmann</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kazama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ideta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Higashide</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chihara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishiko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yanagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chuman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yamashiro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gotoh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Astakhov</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Osman</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Al-Obeidan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Owaidhah</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al-Jasim</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Al Shahwan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fogarty</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Leo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yetkin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>O&#x0011f;uz</surname>
                <given-names>&#x000c7;</given-names>
              </name>
              <name>
                <surname>Kanavi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Beni</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Yazdani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akopov</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Toh</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meah</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Peh</surname>
                <given-names>SQ</given-names>
              </name>
              <name>
                <surname>Kosior-Jarecka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lukasik</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Krumbiegel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vithana</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Challa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rautenbach</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ziskind</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narendran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vijayan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Guadarrama-Vallejo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Welge-Luessen</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Mardin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schloetzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hillmer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Herms</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moebus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>N&#x000f6;then</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Weisschuh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lischinsky</surname>
                <given-names>I</given-names>
              </name>
              <collab>Blue Mountains Eye Study GWAS Team</collab>
              <collab>Wellcome Trust Case Control Consortium 2</collab>
              <name>
                <surname>Crowston</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Coote</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Vysochinskaya</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Founti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chatzikyriakidou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lambropoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anastasopoulos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>May-Bolchakova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alward</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liebmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chowbay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schaeffeler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Frezzotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fingert</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Inatani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tashiro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edward</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wiggs</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pasutto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Topouzis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dubina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sundaresan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Khor</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome.</article-title>
            <source>Nat Genet</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-92</page-range>
            <pub-id pub-id-type="pmid">25706626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yilmaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tamer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ates</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Atik</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Is GST gene polymorphism a risk factor in developing exfoliation syndrome?</article-title>
            <source>Curr Eye Res</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>575</fpage>
            <page-range>575-81</page-range>
            <pub-id pub-id-type="pmid">16020292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapuganti</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bharati</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Alone</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Genetic variants and haplotypes in fibulin-5 (FBLN5) are associated with pseudoexfoliation glaucoma but not with pseudoexfoliation syndrome.</article-title>
            <source>Biosci Rep</source>
            <year>2023</year>
            <month>Mar</month>
            <day>31</day>
            <volume>43</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">36794549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chataway</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klebe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chegeni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ronci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voelcker</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Novel protein constituents of pathological ocular pseudoexfoliation syndrome deposits identified with mass spectrometry.</article-title>
            <source>Mol Vis</source>
            <year>2018</year>
            <volume>24</volume>
            <fpage>801</fpage>
            <page-range>801-817</page-range>
            <pub-id pub-id-type="pmid">30713420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karaca</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Palamar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akgun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aytacoglu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aykut</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozkinay</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of CNTNAP2 gene rs2107856 polymorphism in Turkish population with pseudoexfoliation syndrome.</article-title>
            <source>Int Ophthalmol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>167</fpage>
            <page-range>167-173</page-range>
            <pub-id pub-id-type="pmid">29260496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapuganti</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Alone</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Quantitative analysis of circulating levels of vimentin, clusterin and fibulin-5 in patients with pseudoexfoliation syndrome and glaucoma.</article-title>
            <source>Exp Eye Res</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>224</volume>
            <fpage>109236</fpage>
            <pub-id pub-id-type="pmid">36055390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Khor</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Genetics of Exfoliation Syndrome.</article-title>
            <source>J Glaucoma</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>27 Suppl 1</volume>
            <fpage>S12</fpage>
            <page-range>S12-S14</page-range>
            <pub-id pub-id-type="pmid">29965897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czop</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gasi&#x00144;ska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kosior-Jarecka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wr&#x000f3;bel-Dudzi&#x00144;ska</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kocki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x0017b;arnowski</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Twenty Novel MicroRNAs in the Aqueous Humor of Pseudoexfoliation Glaucoma Patients.</article-title>
            <source>Cells</source>
            <year>2023</year>
            <month>Feb</month>
            <day>24</day>
            <volume>12</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">36899874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiwani</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Exfoliation Syndrome and Solar Exposure: New Epidemiological Insights Into the Pathophysiology of the Disease.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2015</year>
            <season>Fall</season>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">26322422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanyuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosner</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wiggs</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Negishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Long-term Alcohol Consumption and Risk of Exfoliation Glaucoma or Glaucoma Suspect Status among United States Health Professionals.</article-title>
            <source>Ophthalmology</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>130</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-197</page-range>
            <pub-id pub-id-type="pmid">36041586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewundara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Exfoliation syndrome: a disease with an environmental component.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-81</page-range>
            <pub-id pub-id-type="pmid">25594763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghaffari Sharaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Damji</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Unsworth</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in risk factors associated with ocular exfoliation syndrome.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-120</page-range>
            <pub-id pub-id-type="pmid">31736276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozkan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Altan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Er</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Gultekin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kura&#x0015f;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Artunay</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>The Role of Oxidative Status in the Pathogenesis of Primary Open-Angle Glaucoma, Pseudoexfolyation Syndrome and Glaucoma.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>352</fpage>
            <page-range>352-360</page-range>
            <pub-id pub-id-type="pmid">35818741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aboobakar</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Stamer</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Allingham</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Major review: Exfoliation syndrome; advances in disease genetics, molecular biology, and epidemiology.</article-title>
            <source>Exp Eye Res</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>154</volume>
            <fpage>88</fpage>
            <page-range>88-103</page-range>
            <pub-id pub-id-type="pmid">27845061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Rabiolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Afifi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nouri-Mahdavi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caprioli</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Fast Visual Field Progression in Glaucoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>207</volume>
            <fpage>268</fpage>
            <page-range>268-278</page-range>
            <pub-id pub-id-type="pmid">31238025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Swiston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Paulson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Conley</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chaya</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wirostko</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Exfoliation Syndrome and Exfoliation Glaucoma in the Navajo Nation.</article-title>
            <source>Vision (Basel)</source>
            <year>2022</year>
            <month>Oct</month>
            <day>03</day>
            <volume>6</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">36278673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forsius</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of pseudoexfoliation of the lens in Finns, Lapps, Icelanders, Eskimos, and Russians.</article-title>
            <source>Trans Ophthalmol Soc U K (1962)</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>296</fpage>
            <page-range>296-8</page-range>
            <pub-id pub-id-type="pmid">298430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faulkner</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Pseudo-exfoliation of the lens among the Navajo Indians.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1971</year>
            <month>Jul</month>
            <day>30</day>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>206</fpage>
            <page-range>206-7</page-range>
            <pub-id pub-id-type="pmid">5571208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wiggs</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Prospects for gene-environment interactions in exfoliation syndrome.</article-title>
            <source>J Glaucoma</source>
            <year>2014</year>
            <season>Oct-Nov</season>
            <volume>23</volume>
            <issue>8 Suppl 1</issue>
            <fpage>S64</fpage>
            <page-range>S64-7</page-range>
            <pub-id pub-id-type="pmid">25275911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorleifsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Sulem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Gudbjartsson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jonasdottir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jonasdottir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stefansdottir</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hardarson</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Petursson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arnarsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Motallebipour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wallerman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wadelius</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gulcher</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Thorsteinsdottir</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jonasson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma.</article-title>
            <source>Science</source>
            <year>2007</year>
            <month>Sep</month>
            <day>07</day>
            <volume>317</volume>
            <issue>5843</issue>
            <fpage>1397</fpage>
            <page-range>1397-400</page-range>
            <pub-id pub-id-type="pmid">17690259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansour</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Konstas</surname>
                <given-names>AGP</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Charbaji</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>El Jawhari</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>A Case-Cohort Study of Exfoliation Risk Factors and Literature Review.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2021</year>
            <season>Jan-Mar</season>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-50</page-range>
            <pub-id pub-id-type="pmid">34321821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yildirim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yasar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gursoy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Colak</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of pseudoexfoliation syndrome and its association with ocular and systemic diseases in Eskisehir, Turkey.</article-title>
            <source>Int J Ophthalmol</source>
            <year>2017</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-134</page-range>
            <pub-id pub-id-type="pmid">28149789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>TCW</given-names>
              </name>
              <name>
                <surname>Bala</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Rapid Glaucoma Disease Progression.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>180</volume>
            <fpage>151</fpage>
            <page-range>151-157</page-range>
            <pub-id pub-id-type="pmid">28624324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasquale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Jiwani</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Zehavi-Dorin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Majd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Turalba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brauner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grosskreutz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borboli-Gerogiannis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greenstein</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loomis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wiggs</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Levkovitch-Verbin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Solar exposure and residential geographic history in relation to exfoliation syndrome in the United States and Israel.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>132</volume>
            <issue>12</issue>
            <fpage>1439</fpage>
            <page-range>1439-45</page-range>
            <pub-id pub-id-type="pmid">25188364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnarsson</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of exfoliation syndrome in the Reykjavik Eye Study.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>87 Thesis 3</volume>
            <fpage>1</fpage>
            <page-range>1-17</page-range>
            <pub-id pub-id-type="pmid">20017735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Exfoliation syndrome.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2001</year>
            <season>Jan-Feb</season>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>265</fpage>
            <page-range>265-315</page-range>
            <pub-id pub-id-type="pmid">11166342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ariga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nivean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Utkarsha</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pseudoexfoliation Syndrome.</article-title>
            <source>J Curr Glaucoma Pract</source>
            <year>2013</year>
            <season>Sep-Dec</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>118</fpage>
            <page-range>118-20</page-range>
            <pub-id pub-id-type="pmid">26997794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x000fc;ksel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karaba&#x0015f;</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Arslan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demirci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ca&#x0011f;lar</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Ocular hemodynamics in pseudoexfoliation syndrome and pseudoexfoliation glaucoma.</article-title>
            <source>Ophthalmology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>1043</fpage>
            <page-range>1043-9</page-range>
            <pub-id pub-id-type="pmid">11382627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
            </person-group>
            <article-title>A histopathologic study of iris changes in pseudoexfoliation syndrome.</article-title>
            <source>Ophthalmology</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>102</volume>
            <issue>9</issue>
            <fpage>1279</fpage>
            <page-range>1279-90</page-range>
            <pub-id pub-id-type="pmid">9097764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rfler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
            </person-group>
            <article-title>Corneal endothelial involvement in pseudoexfoliation syndrome.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1993</year>
            <month>May</month>
            <volume>111</volume>
            <issue>5</issue>
            <fpage>666</fpage>
            <page-range>666-74</page-range>
            <pub-id pub-id-type="pmid">8489451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ocular and systemic manifestations of exfoliation syndrome.</article-title>
            <source>J Glaucoma</source>
            <year>2014</year>
            <season>Oct-Nov</season>
            <volume>23</volume>
            <issue>8 Suppl 1</issue>
            <fpage>S1</fpage>
            <page-range>S1-8</page-range>
            <pub-id pub-id-type="pmid">25275896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
            </person-group>
            <article-title>A histopathologic study of zonular instability in pseudoexfoliation syndrome.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1994</year>
            <month>Dec</month>
            <day>15</day>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>730</fpage>
            <page-range>730-43</page-range>
            <pub-id pub-id-type="pmid">7977599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>J&#x000fc;nemann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Unilateral or asymmetric PEX syndrome? An electron microscopy study].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>217</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-8</page-range>
            <pub-id pub-id-type="pmid">11022664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kivel&#x000e4;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hietanen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Uusitalo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autopsy analysis of clinically unilateral exfoliation syndrome.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>2008</fpage>
            <page-range>2008-15</page-range>
            <pub-id pub-id-type="pmid">9331264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SUNDE</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>On the so-called senile exfoliation of the anterior lens capsule; a clinical and anatomical study.</article-title>
            <source>Acta Ophthalmol Suppl</source>
            <year>1956</year>
            <issue>Suppl 45</issue>
            <fpage>1</fpage>
            <page-range>1-85</page-range>
            <pub-id pub-id-type="pmid">13339292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pigment dispersion syndrome: A brief overview.</article-title>
            <source>J Clin Transl Res</source>
            <year>2022</year>
            <month>Oct</month>
            <day>31</day>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>344</fpage>
            <page-range>344-350</page-range>
            <pub-id pub-id-type="pmid">36518550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okugawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oshika</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Morphological study of corneal endothelium and corneal thickness in pseudoexfoliation syndrome.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>2003</year>
            <season>May-Jun</season>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-9</page-range>
            <pub-id pub-id-type="pmid">12782156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aasved</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Incidence of defects in the pigmented pupillary ruff in eyes with and without fibrillopathia epitheliocapsularis (so-called senile exfoliation or pseudoexfoliation of the anterior lens capsule).</article-title>
            <source>Acta Ophthalmol (Copenh)</source>
            <year>1973</year>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>710</fpage>
            <page-range>710-5</page-range>
            <pub-id pub-id-type="pmid">4801166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puska</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Lens opacity in unilateral exfoliation syndrome with or without glaucoma.</article-title>
            <source>Acta Ophthalmol (Copenh)</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-6</page-range>
            <pub-id pub-id-type="pmid">7976257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rumelaitiene</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Speckauskas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tamosiunas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radisauskas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Zali&#x0016b;niene</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Exploring association between pseudoexfoliation syndrome and ocular aging.</article-title>
            <source>Int Ophthalmol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>847</fpage>
            <page-range>847-857</page-range>
            <pub-id pub-id-type="pmid">36127504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sternfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zahavi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geffen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pereg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Megiddo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaton</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Pseudoexfoliation Syndrome in Pseudophakic Patients.</article-title>
            <source>Ophthalmic Res</source>
            <year>2021</year>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">32353850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SAMPAOLESI</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>AMALRIC</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>BESSOU</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[On early diagnosis and heredity in capsular pseudoexfoliation of the crystalline lens].</article-title>
            <source>Arch Oftalmol B Aires</source>
            <year>1961</year>
            <month>Jul</month>
            <volume>36</volume>
            <fpage>159</fpage>
            <page-range>159-64</page-range>
            <pub-id pub-id-type="pmid">14496647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <collab>Medscape</collab>
            </person-group>
            <article-title>Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up.</article-title>
            <source>Eye (Lond)</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>784</fpage>
            <page-range>784-95</page-range>
            <pub-id pub-id-type="pmid">27174381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r56">
          <label>56</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mahabadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Open Angle Glaucoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">28722917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salvetat</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>How to Measure Intraocular Pressure: An Updated Review of Various Tonometers.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Aug</month>
            <day>27</day>
            <volume>10</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">34501306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brusini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Miglior</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Corneal thickness and functional damage in patients with ocular hypertension.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-201</page-range>
            <pub-id pub-id-type="pmid">15812759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayala</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for visual field progression in newly diagnosed exfoliation glaucoma patients in Sweden.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Jun</month>
            <day>24</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>10763</fpage>
            <pub-id pub-id-type="pmid">35750795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness, Functional Subzones, and Macular Ganglion Cell-Inner Plexiform Layer in Differentiating Patients With Mild, Moderate, and Severe Open-angle Glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>761</fpage>
            <page-range>761-766</page-range>
            <pub-id pub-id-type="pmid">32657819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todorovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>&#x00160;arenac Vulovi&#x00107;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sre&#x00107;kovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jovanovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petrovi&#x00107;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>THE EFFECT OF PRIMARY ARGON LASER TRABECULOPLASTY ON INTRAOCULAR PRESSURE REDUCTION AND QUALITY OF LIFE IN PATIENTS WITH PSEUDOEXFOLIATION GLAUCOMA.</article-title>
            <source>Acta Clin Croat</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-236</page-range>
            <pub-id pub-id-type="pmid">34744272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sanvicente</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hark</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shiuey</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonafede</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hamershock</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Withers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2022</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>1538</fpage>
            <page-range>1538-1546</page-range>
            <pub-id pub-id-type="pmid">34041935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pose-Bazarra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Valladares</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-de-Ullibarri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Surgical and laser interventions for pseudoexfoliation glaucoma systematic review of randomized controlled trials.</article-title>
            <source>Eye (Lond)</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1551</fpage>
            <page-range>1551-1561</page-range>
            <pub-id pub-id-type="pmid">33564134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tekcan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mangan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>&#x00130;mamoglu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Uneventful Phacoemulsification after Trabeculectomy in Pseudoexfoliation Glaucoma versus Primary Open-Angle Glaucoma.</article-title>
            <source>Ophthalmic Res</source>
            <year>2023</year>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>672</fpage>
            <page-range>672-680</page-range>
            <pub-id pub-id-type="pmid">36822166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fea</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Laffi</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Economou</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Caselgrandi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sacchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study.</article-title>
            <source>Ophthalmol Glaucoma</source>
            <year>2022</year>
            <season>Mar-Apr</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-218</page-range>
            <pub-id pub-id-type="pmid">34478904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Cataract versus combined surgery in pseudoexfoliation glaucoma.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>797</fpage>
            <page-range>797-802</page-range>
            <pub-id pub-id-type="pmid">36872681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>The medical and surgical management of pseudoexfoliation glaucoma.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2008</year>
            <season>Fall</season>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>95</fpage>
            <page-range>95-113</page-range>
            <pub-id pub-id-type="pmid">18936639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shingleton</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Crandall</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>II</given-names>
              </name>
            </person-group>
            <article-title>Pseudoexfoliation and the cataract surgeon: preoperative, intraoperative, and postoperative issues related to intraocular pressure, cataract, and intraocular lenses.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1101</fpage>
            <page-range>1101-20</page-range>
            <pub-id pub-id-type="pmid">19465298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Singanwad</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Frequency and surgical difficulties associated with pseudoexfoliation syndrome among Indian rural population scheduled for cataract surgery: Hospital-based data.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-226</page-range>
            <pub-id pub-id-type="pmid">30672474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghaffari Sharaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waduthanthri</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Crichton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Damji</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Unsworth</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Towards preventing exfoliation glaucoma by targeting and removing fibrillar aggregates associated with exfoliation syndrome.</article-title>
            <source>J Nanobiotechnology</source>
            <year>2022</year>
            <month>Oct</month>
            <day>27</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>459</fpage>
            <pub-id pub-id-type="pmid">36303134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomczyk-Socha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Turno-Kr&#x00119;cicka</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Importance of MicroRNA Expression in Pseudoexfoliation Syndrome.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Oct</month>
            <day>31</day>
            <volume>23</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">36362020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benincasa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Napoli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical Role of Epigenetics and Network Analysis in Eye Diseases: A Translational Science Review.</article-title>
            <source>J Ophthalmol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>2424956</fpage>
            <pub-id pub-id-type="pmid">31976085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Extracellular, stem cells and regenerative ophthalmology.</article-title>
            <source>J Glaucoma</source>
            <year>2014</year>
            <season>Oct-Nov</season>
            <volume>23</volume>
            <issue>8 Suppl 1</issue>
            <fpage>S30</fpage>
            <page-range>S30-3</page-range>
            <pub-id pub-id-type="pmid">25275901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cetinel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montemagno</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nanotechnology Applications for Glaucoma.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-8</page-range>
            <pub-id pub-id-type="pmid">26693592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Lipson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crean</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2013</year>
            <month>Dec</month>
            <day>02</day>
            <volume>54</volume>
            <issue>13</issue>
            <fpage>7836</fpage>
            <page-range>7836-48</page-range>
            <pub-id pub-id-type="pmid">24204045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahn</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy.</article-title>
            <source>Bioengineering (Basel)</source>
            <year>2023</year>
            <month>Feb</month>
            <day>07</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36829717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r77">
          <label>77</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Pigment Dispersion Glaucoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35593820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scuderi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Contestabile</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Scuderi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Librando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fenicia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pigment dispersion syndrome and pigmentary glaucoma: a review and update.</article-title>
            <source>Int Ophthalmol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>1651</fpage>
            <page-range>1651-1662</page-range>
            <pub-id pub-id-type="pmid">29721842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karp</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Culbertson</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>True exfoliation of the lens capsule.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>117</volume>
            <issue>8</issue>
            <fpage>1078</fpage>
            <page-range>1078-80</page-range>
            <pub-id pub-id-type="pmid">10448754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Futa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kojima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Familial amyloidotic polyneuropathy: ocular manifestations with clinicopathological observation.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>1984</year>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-98</page-range>
            <pub-id pub-id-type="pmid">6098757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dangwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guleria</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jakhmola</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma in Adults-diagnosis, Management, and Prediagnosis to End-stage, Categorizing Glaucoma's Stages: A Review.</article-title>
            <source>J Curr Glaucoma Pract</source>
            <year>2022</year>
            <season>Sep-Dec</season>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-178</page-range>
            <pub-id pub-id-type="pmid">36793264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribeiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbosa-Breda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Faria Pereira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o-Reis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>E Silva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B Melo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Evaluation of the Manchester Triage System in Patients with Acute Primary Angle Closure Attack: A Retrospective Study].</article-title>
            <source>Acta Med Port</source>
            <year>2023</year>
            <month>Nov</month>
            <day>02</day>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>698</fpage>
            <page-range>698-705</page-range>
            <pub-id pub-id-type="pmid">36929920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140078.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damji</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Weis</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Association of pseudoexfoliation syndrome with cardiovascular and cerebrovascular disease: a systematic review and meta-analysis.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-372</page-range>
            <pub-id pub-id-type="pmid">30119791</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
